(RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expansion of their global collaboration to develop and commercialize four next-generation, long-acting immunology antibodies targeting type 2 inflammation.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.